Morgan L. Bixby, PhD

home / authors / morgan-l-bixby-bs

Bixby is a current fellow with the Association of Public Health Laboratories/ Centers for Disease Control and Prevention following recent completion of her PhD in the Hirsch laboratory.

Articles

What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

Morgan L. Bixby, PhD;Jenna Salay, BS;Elizabeth B. Hirsch, PharmD, RPH, FIDSA

November 4th 2024

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.

What’s New in 2023 From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

Morgan L. Bixby, PhD;Dina Zheng, PharmD Candidate;Elizabeth B. Hirsch, PharmD, RPH, FIDSA

October 25th 2023

This year's Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing provided updated breakpoints on therapies.

What’s New in 2022 From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

Elizabeth B. Hirsch, PharmD, RPH, FIDSA;Morgan L. Bixby, PhD

October 26th 2022

The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing held a virtual winter meeting and a hybrid summer meeting in 2022. Ad hoc working groups have several breakpoint revisions underway for multiple organism-drug combinations.